obesity drug news today glp-1 september 29 2025 President Trump announced that Medicare will cover semaglutide (Wegovy) and tirzepatide (Zepbound) for weight management indications for people with obesity. Our senior staff writer Kristen Monaco Use of diabetes and anti-obesity

Unfortunately, it appears the company no longer updates this catalog

But again, it's 140 degrees Fahrenheit, so it's an infrared sauna, and it's been shown to improve a variety of coronary heart disease, and heart-related conditions, there've been some improvements

The Wegovy pill was approved by the FDA in December 2025 as the first oral GLP-1 for weight loss

Blue Cross Blue Shield plans cover some weight loss medications, yet real-world patients frequently encounter barriers including prior authorization requirements, step therapy protocols, and coverage exclusions

This once-daily tablet supports appetite regulation and digestion, making weight management more accessible for individuals who prefer an oral medication